Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Several other equities analysts have also commented on the company. Bank of America upped their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research note on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 15th. Sanford C. Bernstein increased their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. HSBC initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price on the stock. Finally, Hsbc Global Res raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $779.45.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $767.96 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The firm has a market cap of $80.71 billion, a PE ratio of 18.39, a P/E/G ratio of 2.21 and a beta of 0.37. The firm has a 50 day simple moving average of $682.40 and a 200-day simple moving average of $600.42. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $790.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the company earned $12.46 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of REGN. Brighton Jones LLC boosted its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the period. Algert Global LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth $288,000. Quantbot Technologies LP boosted its position in Regeneron Pharmaceuticals by 234.1% in the 1st quarter. Quantbot Technologies LP now owns 1,764 shares of the biopharmaceutical company’s stock valued at $1,119,000 after buying an additional 1,236 shares during the last quarter. CW Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at about $920,000. Finally, Ameriprise Financial Inc. grew its stake in shares of Regeneron Pharmaceuticals by 4.2% during the first quarter. Ameriprise Financial Inc. now owns 340,145 shares of the biopharmaceutical company’s stock valued at $215,571,000 after acquiring an additional 13,594 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.